2021 | ||
---|---|---|
In € | Amounts allocated | Amounts paid |
Fixed remuneration | 1,333,333 | 1,333,333 |
Annual variable remuneration(1) | 1,552,667 | N/A |
Exceptional remuneration | - | - |
Remuneration for term of office as Director | - | - |
Benefits in kind | - | - |
TOTAL | 2,886,000 | 1,333,333 |
(1) The variable remuneration due for year N is paid in N+1. The variable remuneration for 2021 will be calculated on a proportional basis and paid subject to the approval of Resolution 12 by the Annual General Meeting on 21 April 2022.
In € | 2021 |
---|---|
Remuneration due in respect of the financial year | Remuneration due in respect of the financial year20212,886,000 |
Value of performance shares granted during the financial year | Value of performance shares granted during the financial year20215,768,780 |
TOTAL | TOTAL20218,654,780 |
N/A.
N/A.
Grant date | Number of ACAs granted | Performance conditions(1) | Grant value(IFRS fair value) | Date of final vesting of all or part of the ACAs | Number of finally vested shares | First possible date of sale of a portion(2) |
---|---|---|---|---|---|---|
Grant date7 October 2021 |
Number of ACAs granted 17,000 |
Performance conditions(1) Yes |
Grant value(IFRS fair value) 5,768,780 |
Date of final vesting of all or part of the ACAs7 October 2025 |
Number of finally vested shares N/A |
First possible date of sale of a portion(2)7 October 2025 |
(1) See the performance conditions described in chapter 7 of this document.
(2) Mr Nicolas Hieronimus, as corporate officer, shall retain 50% of the fully vested shares in registered form until the end of his term of corporate office. Mr Nicolas Hieronimus has undertaken not to enter into any risk hedging transactions.
N/A.